The class of "RIKEN cDNA 4933416I08 Gene Inhibitors" is characterized by a diverse array of chemical compounds, each exhibiting unique biochemical properties that enable them to modulate various cellular signaling pathways. These compounds, though not directly linked to the RIKEN cDNA 4933416I08 gene due to the lack of specific scientific data, are known to influence key cellular processes that could indirectly impact the function of proteins encoded by this gene.
For instance, Axitinib and Pazopanib are known to inhibit tyrosine kinases involved in cell growth and angiogenesis, potentially altering signaling pathways that the RIKEN cDNA 4933416I08-encoded protein may participate in. Bosutinib and Dasatinib target specific tyrosine kinases like Src/Abl, thereby influencing cell proliferation and survival. Similarly, Crizotinib's inhibition of ALK, MET, and ROS1 tyrosine kinases can affect pathways related to cell differentiation and growth.
Erlotinib and Gefitinib specifically inhibit the EGFR tyrosine kinase, a key player in many cellular signaling pathways related to proliferation and apoptosis. Imatinib, targeting BCR-ABL, c-KIT, and PDGFR tyrosine kinases, impacts multiple pathways involved in cell proliferation and survival. Lapatinib's dual inhibition of EGFR and HER2 tyrosine kinases makes it significant in affecting pathways related to cell growth and survival.
Nilotinib's selective inhibition of BCR-ABL tyrosine kinase highlights its potential in influencing specific cell signaling pathways. Sorafenib and Sunitinib, by inhibiting multiple tyrosine kinases, exhibit a broad spectrum of activity affecting processes like cell proliferation, angiogenesis, and apoptosis.
These chemicals represent a comprehensive approach to understanding and modulating cellular signaling pathways. They provide insights into how different biochemical interactions can influence the activity of proteins encoded by genes like the RIKEN cDNA 4933416I08. By acting at various levels of cellular signaling, from receptor tyrosine kinases to downstream signaling molecules, these inhibitors contribute to our understanding of the complex network of interactions within the cell. Their diverse mechanisms of action highlight the intricate balance of cellular processes and offer a window into the potential regulation of proteins similar to those encoded by the RIKEN cDNA 4933416I08 gene.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | ¥530.00 ¥1636.00 | 51 | |
广谱酪氨酸激酶抑制剂,可能影响细胞增殖和存活的多种信号通路。 | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | ¥835.00 ¥1343.00 | 33 | |
抑制表皮生长因子受体酪氨酸激酶,可能影响细胞增殖和凋亡途径。 | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | ¥699.00 ¥1264.00 ¥2414.00 ¥3858.00 | 74 | |
靶向表皮生长因子受体酪氨酸激酶,可能会影响参与细胞生长和分裂的信号通路。 | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | ¥282.00 ¥1320.00 ¥2358.00 | 27 | |
抑制 BCR-ABL、c-KIT 和 PDGFR 酪氨酸激酶,可能影响细胞增殖和凋亡途径。 | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | ¥4648.00 | 32 | |
表皮生长因子受体和 HER2 酪氨酸激酶的双重抑制剂,可能影响细胞生长和存活途径。 | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | ¥2313.00 ¥4569.00 | 9 | |
选择性抑制 BCR-ABL 酪氨酸激酶,可能会影响细胞增殖和信号通路。 | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | ¥1433.00 ¥2008.00 | 2 | |
抑制VEGFR、PDGFR和KIT酪氨酸激酶,可能影响血管生成和细胞生长途径。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | ¥632.00 ¥2933.00 ¥4693.00 | 129 | |
抑制多种酪氨酸激酶,可能影响细胞增殖、血管生成和细胞凋亡途径。 | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | ¥1692.00 ¥10379.00 | 5 | |
抑制多种酪氨酸激酶,可能会影响血管生成和肿瘤细胞增殖。 |